Yasuo Miyoshi

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Locally Advanced

Early Breast Cancer

Endoplasmic Reticulum

Top Venues

Breast cancer (Tokyo, Japan)

Cancer research

World journal of surgical oncology

Journal of surgical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Reiko Fukui, Takahiro Watanabe, Koji Morimoto, Yukie Fujimoto, Masayuki Nagahashi, Eri Ishikawa, Seiichi Hirota, Yasuo Miyoshi
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Reiko Fukui, Takahiro Watanabe, Koji Morimoto, Yukie Fujimoto, Masayuki Nagahashi, Eri Ishikawa, Seiichi Hirota, Yasuo Miyoshi
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Reiko Fukui, Takahiro Watanabe, Koji Morimoto, Yukie Fujimoto, Masayuki Nagahashi, Eri Ishikawa, Seiichi Hirota, Yasuo Miyoshi
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al. Breast cancer (Tokyo, Japan) (2024)
Reiko Fukui, Takahiro Watanabe, Koji Morimoto, Yukie Fujimoto, Masayuki Nagahashi, Eri Ishikawa, Seiichi Hirota, Yasuo Miyoshi
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Reiko Fukui, Takahiro Watanabe, Koji Morimoto, Yukie Fujimoto, Masayuki Nagahashi, Eri Ishikawa, Seiichi Hirota, Yasuo Miyoshi
An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers. Breast cancer (Tokyo, Japan) (2023)
Ayako Bun, Masayuki Nagahashi, Mamiko Kuroiwa, Miki Komatsu, Yasuo Miyoshi
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin. Breast cancer research and treatment (2023)
Yasuo Miyoshi, Yuta Yoshimura, Kenichi Saito, Kenzo Muramoto, Michiko Sugawara, Karenza Alexis, Kenichi Nomoto, Seigo Nakamura, Toshiaki Saeki, Junichiro Watanabe, Jose Manuel Perez-Garcia, Javier Cortes
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study. Breast cancer (Tokyo, Japan) 27 (4) (2020)
Tomoko Higuchi, Yukie Fujimoto, Hiromi Ozawa, Ayako Bun, Reiko Fukui, Yoshimasa Miyagawa, Michiko Imamura, Kazuhiro Kitajima, Koichiro Yamakado, Yasuo Miyoshi
Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy. Annals of surgical oncology 26 (7) (2019)
Yukie Fujimoto, Natsuko Inoue, Koji Morimoto, Takahiro Watanabe, Seiichi Hirota, Michiko Imamura, Yosuke Matsushita, Toyomasa Katagiri, Haruki Okamura, Yasuo Miyoshi
Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer science 111 (1) (2019)
Yukie Fujimoto, Takahiro Watanabe, Akira I Hida, Tomoko Higuchi, Yoshimasa Miyagawa, Hiromi Ozawa, Ayako Bun, Reiko Fukui, Atsushi Sata, Michiko Imamura, Seiichi Hirota, Yasuo Miyoshi
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Breast cancer (Tokyo, Japan) 26 (6) (2019)
Yukie Fujimoto, Tomoko Higuchi, Arisa Nishimukai, Yoshimasa Miyagawa, Ayako Kira, Hiromi Ozawa, Ayako Bun, Michiko Imamura, Yasuo Miyoshi
High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. Journal of surgical oncology 118 (1) (2018)
Wenwen Wu, Nana Rokutanda, Jun Takeuchi, Yongqiang Lai, Reo Maruyama, Yukiko Togashi, Hiroyuki Nishikawa, Naoko Arai, Yasuo Miyoshi, Nao Suzuki, Yasushi Saeki, Keiji Tanaka, Tomohiko Ohta
HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA. Cancer research 78 (22) (2018)
Michiko Imamura, Takashi Morimoto, Takashi Nomura, Shintaro Michishita, Arisa Nishimukai, Tomoko Higuchi, Yukie Fujimoto, Yoshimasa Miyagawa, Ayako Kira, Keiko Murase, Kazuhiro Araki, Yuichi Takatsuka, Koshi Oh, Yoshikazu Masai, Kouhei Akazawa, Yasuo Miyoshi
Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World journal of surgical oncology 16 (1) (2018)